These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


187 related items for PubMed ID: 12506681

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial.
    Mulder CJ, Westerveld BD, Smit JM, Oudkerk Pool M, Otten MH, Tan TG, van Milligen de Wit AW, de Groot GH, Dutch omeprazole MUPS study group.
    Eur J Gastroenterol Hepatol; 2002 Jun; 14(6):649-56. PubMed ID: 12072599
    [Abstract] [Full Text] [Related]

  • 5. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion.
    Metz DC.
    Digestion; 2000 Jun; 62(2-3):73-81. PubMed ID: 11025353
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Stability of pantoprazole in an extemporaneously compounded oral liquid.
    Dentinger PJ, Swenson CF, Anaizi NH.
    Am J Health Syst Pharm; 2002 May 15; 59(10):953-6. PubMed ID: 12040734
    [No Abstract] [Full Text] [Related]

  • 9. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study.
    Körner T, Schütze K, van Leendert RJ, Fumagalli I, Costa Neves B, Bohuschke M, Gatz G.
    Digestion; 2003 May 15; 67(1-2):6-13. PubMed ID: 12743434
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
    Kambia NK, Luyckx M, Dine T, Dupin-Spriet T, Gressier B, Brunet C.
    J Clin Pharm Ther; 2009 Feb 15; 34(1):25-31. PubMed ID: 19125900
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis.
    Bardhan KD, Van Rensburg C.
    Aliment Pharmacol Ther; 2001 Oct 15; 15(10):1585-91. PubMed ID: 11563998
    [Abstract] [Full Text] [Related]

  • 16. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
    Ramdani A, Mignon M, Samoyeau R.
    Gastroenterol Clin Biol; 2002 Apr 15; 26(4):355-9. PubMed ID: 12070410
    [Abstract] [Full Text] [Related]

  • 17. Intragastric pH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer.
    van Rensburg CJ, Hartmann M, Thorpe A, Venter L, Theron I, Lühmann R, Wurst W.
    Am J Gastroenterol; 2003 Dec 15; 98(12):2635-41. PubMed ID: 14687809
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy and safety of intravenously administered pantoprazole in the treatment of gastrinoma].
    Modlin IM.
    Recenti Prog Med; 2001 Dec 15; 92(7-8):456-61. PubMed ID: 11475787
    [Abstract] [Full Text] [Related]

  • 19. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
    Metz DC, Amer F, Hunt B, Vakily M, Kukulka MJ, Samra N.
    Aliment Pharmacol Ther; 2006 Apr 01; 23(7):985-95. PubMed ID: 16573801
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 10.